Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. CMTM4 inhibits gastric tumorigenesis and metastasis.Journal of gastrointestinal oncology · 2024
   Article
2. Current Opinions on the Relationship Between CMTM Family and Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2023
   Review
3. Molecular Characterizations of Gynecologic Carcinosarcomas: A Focus on the Immune Microenvironment.Cancers · 2022
   Review
4. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.BMC cancer · 2022
   Article
5. CMTM6 knockdown prevents glioma progression by inactivating the mTOR pathway.Annals of translational medicine · 2022
   Article
6. CMTM6, a potential immunotherapy target.Journal of cancer research and clinical oncology · 2022
   Review
7. CMTM family proteins 1-8: roles in cancer biological processes and potential clinical value.Cancer biology & medicine · 2020
   Review
8. Association Between Intra-Tumoral Immune Response and Programmed Death Ligand 1 (PD-L1) in Gastric Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2019
   Article
9. The Role of Epstein-Barr Virus in Cervical Cancer: A Brief Update.Frontiers in oncology · 2018
   Review

Corrections and comments

• Comment on
  Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.2017
• Comment on
  CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.2017

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.